MW151-101: First-in-human Study of MW151

NCT04120233 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Drug Toxicity

Interventions

DRUG: Placebo
DRUG: MW151, 10mg
DRUG: MW151, 20mg
DRUG: MW151, 40mg
DRUG: MW151, 80mg
DRUG: MW151, 160mg

Sponsor

Linda Van Eldik

Collaborators

[object Object]
[object Object]